Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21436905 | 0.93 | SMN1; SMN2 (0.64) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL31194744 | 0.92 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL1119481 | 0.92 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL10604837 | 0.88 | EGFR (0.65) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL4295650 | 0.88 | FOLH1 (0.62) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL10604427 | 0.88 | HPGD (0.54) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL4161097 | 0.87 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL1437989 | 0.87 | FFAR4 (0.58) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL22325357 | 0.87 | HPGD (0.53) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL28979208 | 0.87 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660014-B1 | ALKALOID DERIVATIVE HAVING ANGIOGENESIS INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SEOUL NAT UNIV R&DB FOUNDATION (KR) | 2023-08-30 | — | — | EP | disclosed |
| US-11168081-B2 | Alkaloid derivative having angiogenesis inhibitory effect, and pharmaceutical composition containing same | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2021-11-09 | — | — | US | disclosed |
| US-20210087185-A1 | ALKALOID DERIVATIVE HAVING ANGIOGENESIS INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2021-03-25 | — | — | US | disclosed |
| EP-3660014-A1 | ALKALOID DERIVATIVE HAVING ANGIOGENESIS INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Seoul National University R&DB Foundation (KR) | 2020-06-03 | — | — | EP | disclosed |
| US-5958910-A | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5877193-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0819681-A2 | N-(4-Aryl-thiazol-2-yl)-sulfonamides and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| US-4470997-A | Esters | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-09-11 | — | — | US | disclosed |
| US-4446141-A | Hypotensive piperidine derivatives | KYOWA HAKKO KOGYO CO. (JP) | 1984-05-01 | — | — | US | disclosed |
| US-4423070-A | DI- AND TRIESTERS OF N-(ACYLAMINOALKYL)-DIHYDROXYPHENYLETHANOLAMINES, ANTIINFLAMMATORY | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1983-12-27 | — | — | US | disclosed |
| EP-0018417-B1 | NOVEL PIPERIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KYOWA HAKKO KOGYO CO., LTD (JP) | 1982-06-30 | — | — | EP | disclosed |
| EP-0018417-A1 | Novel piperidine derivatives and pharmaceutical compositions containing them | KYOWA HAKKO KOGYO CO., LTD (JP) | 1980-11-12 | — | — | EP | disclosed |
| US-4137328-A | CONGESTIVE HEART FAILURE | PFIZER INC. (US) | 1979-01-30 | — | — | US | disclosed |
| US-3966814-A | PERIPHERAL VASODILATORS, ANTIHISTAMINES, SPASMOLYTICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168081-B2 | Alkaloid derivative having angiogenesis inhibitory effect, and pharmaceutical composition containing same | GPR119, GIPR, UACA | NPC1 3764/4885RAB9A 299/4885SMN1; SMN2 1467/4885 |
| US-20210087185-A1 | ALKALOID DERIVATIVE HAVING ANGIOGENESIS INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | GIPR, VEGFA, UACA | NPC1 3477/4885RAB9A 650/4885SMN1; SMN2 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.